"Quinazolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011799
|
| MeSH Number(s) |
D03.633.100.786
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinazolines".
Below are MeSH descriptors whose meaning is more specific than "Quinazolines".
This graph shows the total number of publications written about "Quinazolines" by people in this website by year, and whether "Quinazolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 5 | 1 | 6 |
| 2004 | 2 | 1 | 3 |
| 2005 | 4 | 2 | 6 |
| 2006 | 3 | 5 | 8 |
| 2007 | 6 | 4 | 10 |
| 2008 | 4 | 5 | 9 |
| 2009 | 4 | 2 | 6 |
| 2010 | 9 | 2 | 11 |
| 2011 | 3 | 5 | 8 |
| 2012 | 9 | 0 | 9 |
| 2013 | 6 | 7 | 13 |
| 2014 | 5 | 5 | 10 |
| 2015 | 5 | 3 | 8 |
| 2016 | 4 | 1 | 5 |
| 2017 | 2 | 3 | 5 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2021 | 3 | 2 | 5 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 4 | 5 |
| 2024 | 1 | 2 | 3 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinazolines" by people in Profiles.
-
ECOG-ACRIN E6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer. Oncologist. 2026 Apr 10; 31(5).
-
Impact of Letermovir for Cytomegalovirus Primary Prophylaxis on Myelosuppression and Immunosuppression in Lung Transplant Recipients. Clin Transplant. 2024 Dec; 38(12):e70033.
-
Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients. Transpl Infect Dis. 2024 Oct; 26(5):e14337.
-
Redirecting raltitrexed from cancer cell thymidylate synthase to Mycobacterium tuberculosis phosphopantetheinyl transferase. Sci Adv. 2024 03 15; 10(11):eadj6406.
-
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 04 15; 130(8):1234-1245.
-
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 07 01; 402(10395):41-53.
-
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.
-
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). J Thorac Oncol. 2023 08; 18(8):1031-1041.
-
Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation. Blood Adv. 2022 05 24; 6(10):3053-3057.